Introdução: A angiogénese é um factor determinante no estabelecimento e desenvolvimento das lesões de endometriose.
INTRODUCTION
Endometriosis is a common gynecological disorder characterized by vascularized growth of endometrium-like tissue outside the uterine cavity. The condition represents one of the most frequent causes of female infertility and chronic pelvic pain, resulting in highly elevated costs in terms of healthcare and loss of productivity.
1 Currently available medical treatments are based on hormonal therapy that blocks ovarian function and provide transient effects, 2 while surgical resection of the lesions is often necessarily extensive and associated with significant morbidity. 3 Since the survival and proliferation of endometriotic implants require neovascularization, 4 the inhibition of angiogenesis has become an attractive strategy for improved control of endometriosis.
MATERIAL AND METHODS
A literature search was performed in PubMed for the articles written in English language, published before January 2014 and focused on the endometriosis-associated angiogenesis. Using the key words 'endometriosis' and 'endometriotic lesion', which were paired with the key words 'angiogenesis', 'vasculogenesis' and 'antiangiogenic drugs', we detected 394 articles. The most pertinent publications, i.e., the original studies focused on angiogenesis in endometriosis, performed in both preclinical models and humans, and previous reviews were included. Their citation lists were reviewed as well. Related book chapters, available to the authors, were consulted for a more comprehensive presentation of the information. Duplicate papers, letters to the editor and case reports we excluded. No institutional approval was required since only previously published data are presented.
Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com prominent in the recto-vaginal implants ( Fig. 1 ) than in the peritoneal lesions which vascularization is more exuberant than that of the ovarian endometriomas. 5 It has been hypothesized that different processes, including retrograde menstruation, coelomic metaplasia, lymphogenic and hematogenic spread of endometrial cells as well as the recruitment and differentiation of bone marrow stem/ progenitor cells may lead to the endometriotic implant establishment. 6 Regardless the exact mechanism(s) that give(s) origin to the endometriotic lesions, their survival is jeopardized by hypoxia, nutrient deprivation and waste metabolite accumulation. Thereby, a critical feature of endometriotic implants is the ability to become vascularized (Fig. 2) .
At least four distinct mechanisms are considered to contribute to the vascularization of endometriotic lesions. They are: (I) sprouting of novel capillary blood vessels from the pre-existing vasculature, a process called angiogenesis; [7] [8] [9] (II) splitting of a single pre-existing vessel in two new vascular segments through the insertion of a tissue pillar, i.e. vascular intussusceptions; 10, 11 (III) elongation/ widening of pre-existing vessels; 12, 13 and (IV) incorporation of circulating endothelial progenitor cells (EPCs) into vessels, a mechanism denominated vasculogenesis.
9,14-16 Each mechanism includes different series of complexly regulated steps. For example, sprouting angiogenesis involves selective activation of endothelial cells (ECs), breakdown of the basement membrane, proliferation and organized migration of ECs, lumen formation, and stabilization of the endothelial tube by forming new basement membrane and mural cell coverage.
17 Neovascularization is principally induced by hypoxia, as depicted in Fig. 2 , while other triggers include tissue injury, inflammation and altered hormonal milieu in patients with endometriosis.
6,12

Molecular drivers of endometriosis-associated angiogenesis
Angiogenesis is initiated when the dynamic balance between pro-angiogenic stimuli and anti-angiogenic factors is shifted in favor of vascular proliferation. Endometriotic implants, particularly early developing lesions, synthesize a range of pro-angiogenic proteins and express lower levels of angiogenesis inhibitors.
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In parallel, gene expression profiling of eutopic endometria from patients with endometriosis has shown up-regulation of multiple pro-angiogenic factors in comparison with endometria from healthy women. [18] [19] [20] Peritoneal fluid from affected women exhibits elevated concentrations of diverse angiogenic growth factors and cytokines, and reduced amounts of antiangiogenic molecules. [21] [22] [23] [24] [25] Equally as in physiological and tumor angiogenesis, vascular endothelial growth factor A (VEGF-A) plays the role of the principal positive angiogenic regulator in endometriotic lesions. VEGF-A specifically inhibits EC apoptosis 26 and acts as a EC mitogen, 27 enhances EC migration, 28 and increases vascular permeability.
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VEGF-A and its principal receptor VEGF-R2 are strongly up-regulated in endometriotic lesions. 20, [30] [31] [32] Importantly, VEGF-A concentration in the peritoneal fluid significantly correlates with the stage of endometriosis.
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In addition to VEGF-A, important pro-angiogenic factors involved in endometriosis-associated angiogenesis are angiopoietins, Ang-1 and Ang-2. Although the expression of both factors is increased in endometriotic lesions, 20 ,34 the shift of the Ang1/Ang2 balance in favor of Ang2 destabilizes pre-existing vessels and makes them prone to sprout. Furthermore, matrix metalloproteases favor angiogenic sprouting by cleaving the extra-cellular matrix, particularly MMP2, which production is stimulated by the activity of endometriotic cells in the peritoneal fluid. 35 Platelet-derived growth factor B (PDGF-B) is regarded as the main promoter of the pericyte investment in neovessels, being significantly over-expressed by eutopic endometrium of endometriosis patients. 4 Many other ubiquitously expressed molecules have been found to enhance angiogenesis in vitro, in animal models of endometriosis and/ or in human samples. 12, [36] [37] [38] [39] [40] Such promoters include cytokines and growth factors secreted by immune and neuroendocrine cells (e.g., interleukins, IL-1β, 6 and 8, tumor necrosis factor-α, TNF-α, and transforming growth factor β, TGF-β). Finally, not only the secreted factors but also several membranebound proteins, that mediate tumor angiogenesis, are likely engaged in the endometriotic neovascularization, such as Dll4/Notch, vascular integrins and ephrins/Eph receptors. [41] [42] [43] The effects of pro-angiogenic stimuli are antagonized by angiostatic factors, i.e. angiogenesis inhibitors that maintain vascular quiescence under physiological conditions. Endogenous angiogenesis inhibitors can be divided into two major groups: (1) extra-cellular matrix and basement membrane components, and (2) growth factors, cytokines and other non-matrix-derived proteins that directly repress ECs.
17 Thrombospondin 1 (TSP1), a large multifunctional extra-cellular matrix glycoprotein, is a prototype of matrixrelated inhibitors, such as endostatin, while angiostatin, the plasminogen cleavage product, is a prominent non matrixderived angiogenesis inhibitor. 44 These natural inhibitors of neovascularization modulate cell survival, proliferation, adhesion, and protease activation. 44, 45 Their proven downregulation or enhanced activity importantly influences angiogenesis and endometriotic lesion expansion. [46] [47] [48] [49] Thereby, endogenous angiogenesis inhibitors possess strong therapeutic potential.
Collectively, up-regulation of VEGF-A, secondary proangiogenic factors and mediators, and suppressed activity of angiogenesis inhibitors trigger the angiogenic switch. The growth and invasiveness of endometriotic lesion is absolutely dependent on the angiogenic switch, triggered and maintained neovascular proliferation. So, the rationale for considering anti-angiogenic strategies for endometriosis patients is based on this dependence. Promising drug candidates are likely to arise from further and more complete understanding of the molecular machinery governing endometriosis-associated angiogenesis.
Therapeutic trials
Development of appropriate bioassays made possible the discovery and assessment of the agents that target endometriosis-associated angiogenesis. 50 These compounds can be classified as either exclusive antiangiogenic agents, which only one known function is the suppression of angiogenesis, or inclusive agents that have anti-angiogenic activity associated with other functions.
17
The first group involves the blockers of pro-angiogenic signaling pathways, endogenous anti-angiogenic factors and their synthetic mimetics (Fig. 3) . In contrast to anticancer drug development, the exclusive anti-angiogenic agents have not yet reached the clinical trials in patients with endometriosis. On the other hand, among 185 clinical trials on endometriosis registered within ClinicalTrials.gov on January 20, 2014, some have been assessing compounds previously demonstrated to act as inclusive anti-angiogenic agents (e.g. PPAR-γ ligands).
Pro-angiogenic signaling blockers:
Since VEGF-A is the key stimulus for endometriosis-associated angiogenesis, various VEGF-A signaling blockers have been initially evaluated in rodent models and/or chicken chorioallantoic membrane assay, including a soluble truncated VEGR-R1 51 and different anti-VEGF-A-antibodies. [51] [52] [53] Indeed, these agents potently inhibited the establishment and growth of endometriotic lesions by disrupting their vascularization. Similar results were later obtained with VEGF-A-targeted gene therapy. However, serious toxicities (hemorrhage, proteinuria, severe hypertension, gastrointestinal perforation, poor wound healing, arterial thrombosis and reversible posterior leuko-encephalopathy syndrome);
17 will probably impede bevacizumab to be ever evaluated in women suffering from endometriosis. In addition, acquired drug resistance causes a serious concern due to redundancy of pro-angiogenic signals involved in the promotion of endometriosisassociated angiogenesis. This might be overcome by targeting multiple pro-angiogenic signaling pathways. For instance, Laschke and colleagues treated endometriotic lesions in a hamster model with two small molecule tyrosine kinase inhibitors, SU5416 and SU6668.
56 While SU5416 only blocks VEGF-A receptors, SU6668 functions as a blocker of VEGF-A, basic fibroblast growth factor (bFGF) and platelet-derived growth factor B (PDGF-B) receptors. As expected, the simultaneous inhibition of three growth factors was significantly more efficient than blockade of VEGF-A signaling alone. Similarly, sorafenib (Nexavar®, Bayer/Onyx Pharmaceuticals), another multikinase inhibitor that interferes with VEGF-R2, VEGF-R3, B-Raf and other tyrosine kinase receptors, was highly efficient in a rat model of induced endometriosis. 57 Despite the risk of cumulative toxicity that cannot be neglected, the concept of combined pathway targeting opens up perspectives for improved control of endometriosis.
Endogenous
and synthetic anti-angiogenic compounds: Contrary to the agents that neutralize proangiogenic factor(s) or block its/their receptor(s) on ECs, endogenous and synthetic angiogenesis inhibitors directly target ECs and block the endothelium to response to proangiogenic factors. Thereby, they are commonly called direct anti-angiogenic agents. Acting on genetically stable ECs, they have been thought to be less prone to induce acquired drug resistance.
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Angiostatin and endostatin are endogenous antiangiogenic agents that have been already evaluated in endometriosis-bearing mice. Angiostatin was assessed in the form of gene therapy that, although effective, exerts strong side effects on the female reproductive organs. 47 On the other hand, various independent studies in mice provide that endostatin and its functional synthetic fragments suppress angiogenesis and endometriosis without toxic effects, including the absence of any interference with the fertility and pregnancy development. 48, 49, 53 Technical problems associated with the synthesis of the required amount of endostatin are probably the main reason that delays the drug progress towards clinical trials in women affected by endometriosis.
The first synthetic anti-angiogenic agent was TNP-470, an analogue of Aspergillus fumigatus antibiotic fumagillin.
By decreasing microvessel density, TNP-470 potently impairs both tumor and endometriosis lesions in different models. 53, 58 However, it is an unsuitable drug candidate due to neurotoxicity and other unacceptable side effects.
In contrast, TNP-470 derivative caplostatin was designed to have improved safety profile, being equally effective against endometriotic lesions in a rodent model. 59 The main disadvantage of caplostatin is its poor oral availability and very short plasma half-life. More recently, lodamin was synthetized by conjugation of TNP-470 and an amphiphilic polymer. The initial assessment of lodamin in mice indicated that the treatment significantly decreases the level of circulating EPSs and the number of endometriotic lesions.
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This result is an additional indicator of the important role for vasculogenesis in the pathogenesis of endometriosis and supports the potential clinical use of non-toxic TNP-470 derivatives.
Inclusive anti-angiogenic agents: Anti-angiogenic activity was discovered as a secondary function of many drugs that had been previously approved for various diseases due to their distinct primary functions. In endometriosis models and/or patients, wide range of compounds, from hormones to anti-inflammatory and lipidlowering drugs have been found to interfere with both lesion growth and their neovascularization, as inclusive antiangiogenic agents (Fig. 3) .
Suppressing the ovarian function, progestins, synthetic testosterone derivative danazol and gonadotropinreleasing hormone (GnRH) agonists have been used in endometriosis patients for decades. There is evidence that these drugs possess anti-angiogenic activity as well. While estrogen increases VEGF-A expression, 33 progesterone, dydrogesterone and dihydrodydrogesterone, 60 such as danazol, 61 reduce VEGF-A levels. Importantly, dienogest, an oral progestin, inhibited development and maturation of neovessels in a rat endometriosis model. 62 In parallel, Khan and colleagues provided data showing that leuprolide acetate, a GnRH agonist, reduces macrophage infiltration and microvessel density in lesions collected from endometriosis patients. 63 Thus, beneficial mechanisms of progestins, danazol and GnRH agonists encompass their angiostatic activity. As previously highlighted, favorable clinical outcomes are not long-lasting and the disease relapses with the cessation of the therapy.
In addition to the above mentioned drugs, dopamine agonists, such as ergot-derived cabergoline, used in gynecology and obstetrics for the treatment of hyperprolactinaemia and suppression of lactation, may cause the regression of endometriotic lesions by inhibiting mitosis and VEGF-A-mediated angiogenesis. [64] [65] [66] Due to its quite favorable safety profile, non-ergot-derived dopamine agonist quinagolide was not only evidenced to be effective in pre-clinical trials, but also progressed to the clinical assessment. By suppressing VEGF-A signaling, proangiogenic cytokines and plasminogen activator inhibitor-1, the drug resulted in a 69.5% reduction of endometriotic lesions, while 35% of them completely vanished, in 9 women that required a surgical intervention and underwent a second-look laparoscopy.
67 Dopamine agonists inhibit angiogenesis in an autocrine fashion by binding to the dopamine receptor D2 (DRD2) on endothelial cells that inactivates VEGFR2. 68 Complementary, quinagolide binding to DRD2 on macrophages has been reported to decreases the expression of VEGF-A mRNA levels. 69 Thus, it is likely that quinagolide also suppresses the endometriosisassociated angiogenesis in a paracrine fashion by decreasing the production of VEGF-A by immune cells within the lesions. 70 Since endometriosis-associated inflammation and angiogenesis are closely related processes, numerous studies have been focused on anti-inflammatory drugs and immunomodulators. The principal enzyme in the conversion of arachidonic acid to prostaglandins, cyclo-oxygenase 2 (COX-2), is over-expressed in endometriotic lesions and eutopic endometrium of affected women, seeming to play multiple roles in the pathogenesis of endometriosis.
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Some COX-2 inhibitors suppress the endometriotic lesion growth, partially by the inhibition of angiogenesis.
72 Such a compound is NS398. 73 Although not all COX-2 inhibitors influence endometriotic lesions (e.g., nimesulid), 51 selective inhibitors that do exert the effects appear as potential drug candidates, but significant cardiovascular side effects restrict their development.
Immunomodulatory agents with proven anti-VRGF-A anti-angiogenic effects on endometriotic lesions include lipoxin A4, rapamycin and pentoxifylline. 74 The last one has been already assessed in patients with endometriosis. 75 Nevertheless, there is still not enough evidence to support the use of pentoxifylline in women affected by endometriosis in terms of fertility promotion and symptoms relief.
Due to pleiotropic effects on energy metabolism, inflammation and angiogenesis, popularly denominated 'lipid-lowering drugs', both statins (simvastatin, atorvastatin, and lovastatin) and peroxisome proliferator-activated receptor (PPAR) ligands (fenofibrate, rosiglitazone, and pioglitazone) have been furthermore considered for potential inclusion in the multimodal management of endometriosis patients. 74 Canadian study indicates that endometriosis patients may benefit from statins due to their inhibitory effect on angiogenesis. 76, 77 Similarly, inclusive anti-angiogenic PPAR-gamma ligands (rosiglitazone and pioglitazone) resulted in the regression of endometriotic implants in rodents, baboons and humans. 74, 78 Beside the efficacy, the risk for myopathies in the case of statins and cardiovascular lateral effects of PPAR-gamma ligands remain to be addressed in the future trials.
Finally, numerous pleiotropic phytochemical agents have been reported to exert anti-angiogenic effects and induce the regression of endometriotic lesions. 74, 79 The principal constituent of green tea, epigallocatechin-3-gallate, has been evidenced to block the VEGF-A expression of cultured hamster endometrial cells, inhibit angiogenesis in vivo and induce regression of endometriosis. [80] [81] [82] Similar effects on the endometriotic lesions and their vessels have been observed in the experiments testing curcumin, a pharmacological active component of Curcuma longa. 83 Puerarin (a compound isolated from Radix puerariae), Djokovic D, et 
4-hydroxybenzyl alcohol (a Gastrodia elata extract) and xanthohumol (a flavonoid purified from Humulus lupulus) have been additionally found to interfere with different steps of the angiogenic process and endometriotic lesion development. [84] [85] [86] Nevertheless, there is a lack of functional pharmaceutical formulations and controlled clinical studies to support the consideration of medicinal herbs and synthetic phytochemical drugs in the treatment of endometriosis. 
DISCUSSION AND CONCLUSION
The validity of the concept of angiogenesis suppression in endometriosis patients has been supported by extensive research evidence. To assess the perspective of antiangiogenic therapy as a treatment for endometriosis, there are three major issues to be considered: the true effectiveness of the treatment, the risk of drug resistance development and the risk of unacceptable side effects.
In the first place, the existing information on the effectiveness of exclusive and most inclusive anti-angiogenic compounds has been obtained in animal models. It is questionable whether the specific mechanisms targeted in these experiments are the same as those that occur in humans where the lesions spontaneously develop and the disease has a chronic character. In accordance with the molecular analyzes of the human samples, the congruence exists in terms of involved signaling pathways, but it is likely that the most appropriate moment for anti-angiogenic treatment is already over when the symptomatic patients typically seek a medical assistance. While angiogenic vessels predominate in early endometriotic lesions, increased percentage of mature vessels characterizes the later stage lesions. 87 Considering this fact, antiangiogenic drugs may effectively inhibit the newly forming lesions, but not later stage implants, particularly the rectovaginal lesions with abundant mature vessel networks.
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Angiogenesis targeting could be suitable for the prevention of recurrent endometriosis associated with currently used pharmacological and surgical treatment modalities. Further studies are required to define the patient profile(s) that will most benefit of anti-angiogenic therapy.
Besides, even if the angiogenesis is targeted in properly selected women (i.e., those with early primary or early relapsing disease), the experience from tumor patients indicates that the lesions may develop drug resistance. Specific suppression of an individual pro-angiogenic pathway will be certainly compensated by up-regulation of other angiogenesis promoters. The use of pleiotropic compounds and simultaneous targeting of different proangiogenic and other mechanisms importantly involved in the pathogenesis of endometrioses may provide improved and prolonged clinical benefit. Additionally, the application of anti-angiogenic compounds in combination with already approved drugs may be also appropriate. Such multimodal therapeutic regimens for endometriosis hypothetically require lower doses of each individual drug, resulting in both increased efficacy and reduced toxicity.
Finally, and of particular concern, are the lateral effects of angiogenesis inhibitors. Generally said, endometriosis is not a life-threatening disease, although malignant neoplasms rarely develop from endometriotic lesions.
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In parallel, most of the affected women are reproductive age individuals without significant comorbidities, desiring to preserve fertility or solve the problem of infertility. For this perspective, promising candidates are inclusive antiangiogenic agents with favorable safety profiles that have already received approvals for the treatment of benign disorders. Alternatively, in the absence of the evidence that endometriosis-specific angiogenic mechanisms exist and can be safely targeted, short-term anti-angiogenic regimens should be considered. Physiological angiogenesis is a fundamental prerequisite for normal reproductive function and embryonic/fetal development. Accordingly, a major challenge in the future research will be identification and validation of anti-angiogenic compounds that do not exert long-term effects on the vascular regeneration within ovaries, uterus and other healthy tissues.
Although a large number of anti-angiogenic agents have been demonstrated to be promising in preclinical studies, currently very few have been tested in humans such as quinagolide and pentoxifylline. Due to the time-consuming nature of the drug discovery and development process, no exclusive anti-angiogenic drug for endometriosis appears to be on the horizon. Industry-sponsored clinical trials that are based on a good risk/profitability balance are likely to access, in the first line, so called neoclassic compounds belonging to the group of inclusive anti-angiogenics (e.g., hormone-related substances, dopamine agonists, and PPAR ligands).
Understanding the pathophysiological mechanisms that promote angiogenesis within the endometriotic lesions is an essential prerequisite for the development of successful therapeutic strategies. Currently, there is a lack of clinical evidence for the efficacy and safety of anti-angiogenic treatments in endometriosis patients. Despite this fact, they hold promise to be effective against the newly forming lesions in the early stages of endometriosis and suitable for the prevention of the recurrent disease after surgery. Thus, a step forward in the care of endometriosis patient may result from targeted anti-angiogenic therapies.
